SCHEMBL6101360

SCHEMBL6101360

COc1cc(CC(=O)Nc2cccc(C=Cc3ccccc3)c2)ccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
APP P05067 1/20 0.56
KMT2A Q03164 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
MEN1 O00255 4/20 0.55
ALDH1A1 P00352 2/20 0.55
TSHR P16473 2/20 0.55
MAPK1 P28482 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55
KDM1A O60341 4/20 0.54
STAT3 P40763 1/20 0.54
GAA P10253 2/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
BCHE P06276 4/20 0.52
ACHE P22303 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101354 1.00 MAPT (0.56) MAPTAPPKMT2ASMN1; SMN2LMNA
SCHEMBL6101644 0.85 SMN1; SMN2 (0.64) MAPTKMT2ASMN1; SMN2LMNAHTT
SCHEMBL6099398 0.84 KMT2A (0.64) MAPTKMT2ASMN1; SMN2LMNAHTT
SCHEMBL6101972 0.83 SNCA (0.64) MAPTAPPKMT2AMEN1ALDH1A1
SCHEMBL6101976 0.83 SNCA (0.64) MAPTAPPKMT2AMEN1ALDH1A1
SCHEMBL6098671 0.83 SMN1; SMN2 (0.57) MAPTKMT2ASMN1; SMN2LMNAHTT
SCHEMBL6100978 0.83 KDM4E (0.65) MAPTKMT2ASMN1; SMN2LMNAHTT
SCHEMBL6098990 0.81 SMN1; SMN2 (0.60) MAPTKMT2ASMN1; SMN2LMNAHTT
SCHEMBL6099937 0.80 ALDH1A1 (0.65) MAPTKMT2ASMN1; SMN2LMNAHTT
SCHEMBL6100235 0.80 BCHE (0.65) MAPTKMT2ASMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US claimed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US claimed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP claimed
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US disclosed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US disclosed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same HRH2, CCR8, CYP2C8 MAPT 4374/4885APP 4227/4885KMT2A 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.